$TWST

Cho Dennis sold $91K of TWST

Cho Dennis (See Remarks) sold 1,070 shares of Twist Bioscience Corp (TWST) at $85.32 on 2026-08-03.

Original reporting
SEC EDGAR · Cho Dennis
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosed open-market sale may modestly influence short-term sentiment, but it does not provide new operational, financial, or regulatory information about TWST.

02

Market read

A routine insider sale is disclosed, offering limited incremental trading signal absent other company-specific catalysts.

03

What to watch

The article does not state the insider’s total compensation, tax obligations, or whether other sales occurred around the same time; absence of a cited 10b5-1 plan may increase speculation but is not proof of information advantage.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, sale dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience officer Cho Dennis filed a Form 4 selling 1,070 shares at $85.3212 on 2026-08-03, totaling $91,293.68.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and should fade unless follow-on selling or other news emerges.

Evidence & confidence

The filing discloses a single insider sale size and price, but provides no new company fundamentals, guidance, or legal/operational developments.

Market effects

Minimal; insider sale does not change biotech/genomics sector fundamentals in the text.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification and do not necessarily signal reduced confidence, especially when the company has no accompanying negative news in the filing.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Cho Dennis

    Officer who sold 1,070 shares at $85.3212 on 2026-08-03.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.